HILLSIDE, N.J., July 14 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc. announced today that it is participating at a conference on “Innovations in Mitigating BioThreats,” a series of presentations and discussions to be held July 18, 2005 in Wilmington, Delaware, organized and hosted by the Fraunhofer USA Center for Molecular Biotechnology, located in the Delaware Technology Park in Newark, Delaware.
The presentations and discussions will cover technological advances for control and prevention of infectious diseases. Among the participants will be the executive board of Fraunhofer-Gesellschaft, leaders from Fraunhofer USA, Inc., government and university officials, representatives from the U.S. Department of Defense, the U.S. Department of Agriculture, the Delaware Economic Development Office, and other national and international health organizations.
Dr. Orn Adalsteinsson, President of InB:Biotechnologies, a wholly-owned subsidiary of Integrated BioPharma, and Dr. Geoffrey Schild, CSO of InB:Biotechnologies, a world-renowned authority on influenza viruses, are among those who will address the group. In addition, Dr. Schild will chair a session on Public Health, with particular emphasis on developing measures for control and prevention of influenza outbreaks.
InB:Biotechnologies is at the forefront of developing biotech solutions to bacterial and viral challenges. A current project involves a plant-derived, oral anthrax vaccine designed to boost immune responses in vaccinated or primed individuals. The project is a team effort between the Naval Medical Research Center, Fraunhofer USA, Inc., and INB: Biotechnologies.
“Our business is health and we are pleased to participate in this conference to promote a better understanding of biological threats, and preventative and counter-measures to these threats,” said E. Gerald Kay, CEO of Integrated Biopharma, Inc.
About Integrated BioPharma Inc (INB)
INB serves the pharmaceutical, biotech and nutraceutical industries. Through its wholly-owned subsidiaries, INB develops, manufactures and distributes products worldwide. Further information can be found on the Company’s website at www.iBioPharma.com.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, internal issues in the sponsoring client and the possible charge relating to changes in operations. Further information on potential risk factors that could affect the company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Contact: Michael Mason (investors) Gregory A. Gould, CFO Allen & Caron Inc. Integrated BioPharma, Inc. 212 691 8087 888 319 6962 michaelm@allencaron.comggould@ibiopharma.com Brian Kennedy (media) brian@allencaron.com
Integrated BioPharma, Inc.
CONTACT: Investors, Michael Mason, +1-212-691-8087,michaelm@allencaron.com, or Media, Brian Kennedy, brian@allencaron.com,both of Allen & Caron Inc., for Integrated BioPharma, Inc.; or Gregory A.Gould, CFO, of Integrated BioPharma, Inc., +1-888-319-6962,ggould@ibiopharma.com
Web site: http://www.iBioPharma.com/
